
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia
Keywords: DDI; drug-drug interaction; β-EST; β-estradiol; HLM; human liver microsomes; IV-IVE; in vitro-in vivo extrapolation; KI; kinase inhibitor; 4MU; 4-methylumbelliferone; LAP; lapatinib; NSB; non-specific binding; PAZ; pazopanib; PRO; propofol; REG; r